Champions Oncology (CSBR) closed at $12.41 in the latest trading session, marking a -1.43% move from the prior day. This change lagged the S&P 500's daily gain of 0.22%. Elsewhere, the Dow gained 0.49%, while the tech-heavy Nasdaq lost 0.15%.
Heading into today, shares of the company had lost 2.02% over the past month, lagging the Medical sector's gain of 0.16% and the S&P 500's loss of 0.57% in that time.
CSBR will be looking to display strength as it nears its next earnings release, which is expected to be December 6, 2018. Meanwhile, our latest consensus estimate is calling for revenue of $6.35 million, up 22.12% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.17 per share and revenue of $25.31 million, which would represent changes of +440% and +25.06%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CSBR. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CSBR is currently a Zacks Rank #3 (Hold).
Investors should also note CSBR's current valuation metrics, including its Forward P/E ratio of 74.06. For comparison, its industry has an average Forward P/E of 17.43, which means CSBR is trading at a premium to the group.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CSBR in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Champions Oncology, Inc. (CSBR) : Free Stock Analysis Report
To read this article on Zacks.com click here.